Hofseth Biocare ASA: New Share Capital registered
September 30 2016 - 1:00AM
Reference is made to the
stock exchange notice published on 20 October 2016 regarding the
private placements with gross proceeds of NOK 165.4 million (the
"Private Placements")
The share capital increase
related to the Private Placements has now been registered with the
Norwegian Register of Business Enterprises. The share capital has
been increased with NOK 110,262,699 through issuance of a
corresponding amount of new shares.
The new share capital is
thus NOK 232,472,265.00 divided by 232,472,265 shares, each with a
par value of NOK 1.
The new shares will be
listed and become tradable on Oslo Axess on or about 3 October
2016.
For further information,
please contact:
Jon Olav Ødegård, CFO of
Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail:
joo@hofsethbiocare.no
About Hofseth BioCare
ASA:
HBC is a Norwegian biotech
company that offers high-value ingredients and finished products
for humans and pets. The company is founded on the core values of
sustainability, traceability and optimal utilization of natural
resources. Through an innovative hydrolysis technology, HBC is able
to preserve the quality of salmon oil, proteins and calcium,
prepared of fresh salmon off-cuts. HBC's objective is to contribute
to the efficient use of marine resources and deliver quality
products for ingredients and finished consumer products in the
nutrition market.
Hofseth BioCare's
headquarters are located in Ålesund, Norway with branches in Oslo,
Chicago, Mumbai and Tokyo. HBC is listed on Oslo Stock Exchange
Axess list with ticker "HBC". More information about Hofseth
BioCare at www.hofsethbiocare.com and
www.facebook.com/hofsethbiocare
This information is subject
to the disclosure requirements pursuant to section 5-12 of the
Norwegian Securities Trading Act.
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Hofseth Biocare ASA via Globenewswire